DXR News

Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

Daxor Corporation Announces $9 Million Registered Direct Offering

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA